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What is microRNA?
Small non-coding double stranded RNAs
Approximately 19-22 nt long
Repress activity of complementary mRNAs
Regulate 30% of mammalian gene products
1 miRNA = hundreds of mRNAs
Have been described in invertebrates and vertebrates:        
worms, fungi, plants, and mammals  
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History of microRNA
 1993, Discover lin-4, the first miRNA in worm, Victor 
Ambrose et al.
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Cell 1993, Vol75;843-54
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History of microRNA
 2000, discover the fist evolutionarily conserved miRNA 
(let-7 ) in worm
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Nature 2000,Vol.403;901-5
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History of microRNA
 2005, hundreds of miRNA gene discovered in human
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Genomic Organization of miRNA Genes
Zhao Y, Srivastava D, TIBS 32:189,2007
Intronic miRNAs often in antisense direction, made from own 
promoter
Exonic miRNAs - non-coding (or in alternatively spliced exons)
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Precursor miRNA Products
Form Stem Loop Structures
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Filipowicz (2008) Nature Review Genetics 9:102-112.
Romaine SP, Tomaszewski M, Condorelli G, Samani
NJ.. 2015;101(12):921-8.
miRNAs Affect Everything
© Frank Slack frank.slack@yale.edu15
Methods of identifying miRs
 Direct cloning
 Computer search of the genome
 MiRNA microarray search in different species
 Construction of miRNA in vitro and targeting known 
gene sequences
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Using bioinformatics tools to identify miRs 
 KEGG: http:// www.genome.jp/kegg
 Target Scan : http://www.targetscan.org
 miRBase: http://www.mirbase.org
 miRWalk: http://www.umm.uni-heidelberg.de
 miRanda :http://www.microrna.org
 miRDB : http:// :mirdb.org
 GEO: www.ncbi.nlm.nih.gov/gds
 miRNAMap: http://mirnamap.mbc.nctu.edu.tw
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Gestational Diabetes Mellitus 
Overview
 Recognize for the first time during pregnancy
 Intolerance to carbohydrates with different intensities.
 The most common medical complication of pregnancy.
 Affects 2 to 9 percent of all pregnancies.
 The prevalence of GDM varies from 1-20%, and is rising 
worldwide
 At risk for type 2 diabetes
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Pathophysiology
 Pregnancy is associated with insulin resistance (IR) and hyperinsulinemia that 
may predispose some women to develop diabetes.
 Hormones and adipokines secreted from the placenta, including tumor necrosis 
factor, human placental lactogen, and human placental growth hormone are 
possible causes of IR in pregnancy. 
 In addition, increased estrogen, progesterone, and cortisol during pregnancy 
contribute to a disruption of the glucose insulin balance
 The development of GDM occurs when a woman’s pancreas does not secrete 
enough insulin
 In addition, increased maternal adipose deposition, decreased exercise, and 
increased caloric intake contribute to this state of relative glucose intolerance.
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insulin sensitivity during pregnancy
 In early pregnancy, insulin secretion increases, while 
insulin sensitivity is unchanged, decreased, or may even 
increase.
 At mid pregnancy, insulin sensitivity starts to decline 
progressively, and became worse during the rest of the 
pregnancy, being worst in the late third trimester.
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Risk factors for GDM
 Obesity
 older maternal age
 past history of GDM
 strong family history of diabetes
 member of an ethnic group with a high prevalence of T2DM
 polycystic ovary syndrome
 persistent glucosuria
 history of delivering big baby (birth weight ≥4000 g)
 history of recurrent abortions
 history of unexplained stillbirths
 history of essential hypertension, or pregnancy-related hypertension
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GDM complications
 Fetal macrosomia
 Damage during delivery
 Polyhydramnios
 Preeclampsia
 Newborn metabolic disorders
 Respiratory distress syndrome
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Screening and diagnosis of GDM
 24-28 weeks of pregnancy in one hour 50 g glucose 
challenge test (GCT)
 plasma glucose levels ≥140mg / dL
 oral glucose tolerance test (OGTT)
 Carpenter and Coustan criteria: impairment in at least two 
stages of four measurement periods.
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Screening and diagnosis of GDM
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Management of GDM
 Achieve maternal near normoglycemic level
 Low-carbohydrate diet , high fibre with caloric restriction
 Frequent small snacks may be needed between meals
 Avoid starvation
 Exercise
Insulin therapy
 Pharmacological interventions                            Glibenclamide
Metformin
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MicroRNA and Diabetes
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miRNAs in glucose homeostasis
Kumar M, Nath S, Prasad HK, Sharma G, Li Y. Protein & cell. 2012;3(10):726-38.27
miRNAs in insulin production and secretion
Kumar M, Nath S, Prasad HK, Sharma G, Li Y. Protein & cell. 2012;3(10):726-38.
28
miRNAs in insulin action
 Shi et al, 2007. of the two genes encoding insulin receptor substrate 
proteins(IRS1 and IRS2), only IRS1 has been identified as a target of miRNAs, 
specifically miR-145 .
 Roggli et al , 2010. implicates miR-34a and miR-146a, as well as miR-21 as 
novel players in β-cell failure elicited by proinflammatory cytokines during the 
development of peri-insulitis that precedes overt diabetes in NOD mice
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miRNAs in insulin action
 Zhu et al , 2011.target genes repressed by let-7 include IGF1R,INSR, IRS2, 
HMGA2, and IGF2BP2. These data support that let-7 is a regulator of glucose 
metabolism and that the let-7family is a potential target for T2D.
 Honardoost M et al, 2014. the role of microRNA 135a in skeletal
muscle insulin resistance in mice
Target is gene INSR (Insulin receptor), which prevents its expression and thus 
reduce the absorption of glucose in the cell.
MiRNA135a is suppressed to reduce hyperglycemia.
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MiRNAs in diabetic complications
Diabetes causes complications in many organs such as:
 Diabetic cardiomyopathy
 Diabetic nephropathy
 Diabetic retinopathy
 Diabetic foot disorders
miRNAs are involved in many of these complications.
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Diabetic cardiomyopathy
Kumar M, Nath S, Prasad HK, Sharma G, Li Y. Protein & cell. 2012;3(10):726-38.
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Diabetic nephropathy
Kumar M, Nath S, Prasad HK, Sharma G, Li Y. Protein & cell. 2012;3(10):726-38.
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Diabetic retinopathy
Kumar M, Nath S, Prasad HK, Sharma G, Li Y. Protein & cell. 2012;3(10):726-38.
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Diabetic foot disorders
Kumar M, Nath S, Prasad HK, Sharma G, Li Y. Protein & cell. 2012;3(10):726-38.
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microRNAs as biomarkers in
plasma or serum
2011 Diana M et al 
 with Title microRNAs in pregnancy
 The study of 44 related articles
 miRNAs present in the maternal circulation may provide a 
new promising diagnostic tool for pregnancy disorders.
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microRNAs as biomarkers in
plasma or serum
2015                     Tsochandaridis M et al 
 with Title Circulating MicroRNAs as Clinical Biomarkers in the Predictions of 
Pregnancy Complications
 The study of 60 related articles
 microRNAs circulating in the maternal plasma might have the potential to be 
noninvasive diagnostic and prognostic biomarkers for pregnancy monitoring. 
 They might prevent the development of gestational disorders and form the basis 
of personalized therapeutic strategies.
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Microrna and Macrosomia
2015                      Li J et al 
 investigated the role of miR-17-92 cluster in macrosomia
 miR-17-92 cluster contribute to macrosomia development by targeting 
regulators of cell cycle pathway. Our findings not only provide a novel
 insight into the molecular mechanisms of macrosomia, but also the clinical value 
of miR-17-92 cluster
 as a predictive biomarker for macrosomia.
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Microrna and Macrosomia
2014 Hua Jiang et al 
 The expression levels of miR-21 were significantly decreased in macrosomia as
 compared to the controls in the third trimester. Receiver operating characteristic 
(ROC) curve analyses showed that the area
 under the ROC curve for miR-21 was 67.7% (sensitivity ¼ 66.7% and 
specificity ¼ 70.0%). Conclusions: miR-21 in maternal
 serum is differentially expressed between macrosomia and controls, and miR-21 
could be used as a candidate biomarker topredict macrosomia.
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miRNA and GDM
2014                    Nir Pillar et al 
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miRNA and GDM
2010 -2014                       Yanan Zhu et al 
 peripheral blood samples were collected from women at 16–19 weeks of pregnancy. 
 Pooled samples from 10 women who were subsequently diagnosed with GDM and from 
10 healthy controls 
 Differential expression of five upregulated miRNAs (hsa-miR-16-5p, hsa-miR-17-5p, 
hsa-miR-19a-3p, hsa-miR-19b-3p, hsa-miR-20a-5p)
 The five miRNAs  were differentially expressed in GDM could serve as noninvasive 
biomarkers.
 thereby contributing to the diagnosis and treatment of this disease.
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miRNA and GDM
2012                      Morales-Prieto et al
 Study of gene expression of microRNAs involved in the 
pregnancy disorder that is on chromosome number 19 and 14
 Expression of these microRNAs direct connection with pregnancy 
disorders
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miRNA and GDM
2011                    Zhao et al 
 a total of 24 women with gestational diabetes and 24 nondiabetic subjects
 serum collected at 16-19 gestational weeks.
 the expression levels of three miRNAs (miR-132, miR-29a and miR-222) 
were significantly decreased in GDM women
 prevent the expression of microRNAs leads to increased insulin induced gene 
expression
 serum miRNAs are differentially expressed between GDM women and 
controls and could be candidate biomarkers for predicting GDM43
miRNA and GDM
2015                     Nir Pillar et al 
 the role of microRNAs as major factors in the pathogenesis
 as an early biomarker for the diagnosis of gestational diabetes
 prevent the development of gestational diabetes
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Exosomes and GDM
2008                    Taylor et al 
 miRNA-203 has been identified in exosomes isolated from women with GDM.
 oxidative stress and hyperglycaemia increase the release of exosomes from the 
placenta into the maternal circulation during in the first trimester of pregnancy
 The characterised of exosomes in the blood of these pre-symptomatic women, 
thus, may be of utility as an early biomarker of disease onset.
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